| API Access | |

Pulse News Wire translates Japanese corporate disclosures filed with the Tokyo Stock Exchange's TDNet system into clear, structured English for institutional investors, hedge funds, and asset managers. Every article on this page is derived directly from an official TDNet filing — including earnings reports, M&A announcements, share buybacks, dividend declarations, and governance changes. Japanese corporate governance is governed by the Companies Act and the Financial Instruments and Exchange Act; timely translation of these disclosures provides a material information advantage for cross-border investors monitoring Tokyo-listed equities.

This corporate disclosure was processed by Pulse News Wire. It represents a primary source document for Japanese equity sector intelligence, translated directly from an official filing submitted to the Tokyo Stock Exchange TDNet system.

Earnings Forecast Upward Revision

View all Kringle Pharma,Inc. disclosures →

TOKYO, Mar 11 (Pulse News Wire) – Kringle Pharma,Inc. (4884) has revised its earnings forecast. FORECAST REVISION SUMMARY: (Unit: ) Revenue Op Profit Ord Profit Net Profit Previous Forecast (A) 72 △1,172 △1,172 △1,173 Revised Forecast (B) 332 △1 △1,018 △1,020 Change (B-A) 260 153 153 153 Prior Year Actual 72 △909 △914 △916 KEY CHANGES: - Net profit forecast raised to △1,020 - Operating profit forecast raised to △1 REASON FOR REVISION: ( ) (260) Ⅲ IND 107

Original Disclosure (PDF)

🟢 Confidence: High AI-translated content.